A novel drug that considerably increases survival for patients with breast cancer, especially those with brain metastases, has been evaluated by LMU researchers.
A new drug that can significantly extend the lives of patients with breast cancer has been successfully tested by LMU researchers. Patients with advanced HER2-positive breast cancer often have brain metastases. Those who suffer from this have limited chance of surviving the next few years while undergoing modern therapies like surgery and radiation therapy. An international team of researchers, co-led by Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital, has now conducted a clinical study to evaluate a new drug.
“With excellent outcomes,” the oncologist says. To date, the results show a significant increase in survival times. The journal Nature Medicine has published the trial’s findings. Based on tumor biological features, breast cancer is classified into various kinds in modern medicine. Since the blood-brain barrier frequently hinders active substances from entering the brain, 50% of patients with advanced breast cancer and the tissue marker HER2 will experience brain metastases, which have not yet been successfully treated with medications. Thus, there is an urgent need for new medications.
Also Read:
Namma Yatri of India Intends to Join the US Market
Factors to Watch Next Week: FIIs, Rate Cut, and Economic Data
